Render Target: STATIC
Render Timestamp: 2024-11-20T12:07:42.528Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-07-12 21:34:06.390
Product last modified at: 2024-10-31T21:00:14.380Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PD-1 (Pembrolizumab Biosimilar) Human mAb #60194

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG4 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    PD-1 (Pembrolizumab Biosimilar) Human mAb is a biosimilar antibody for Pembrolizumab. Pembrolizumab is a human monoclonal antibody directed against PD-1 that is dessigned to function as a immune checkpoint inhibitor by disrupting the interaction between PD-L1 and PD-1.
    Endotoxin <0.1 EU/μg of protein

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    PD-1 (Pembrolizumab Biosimilar) Human mAb was confirmed to bind to its intended target protein PD-1 using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    PD-1 (Pembrolizumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Pembrolizumab is an antibody that is directed against the extracellular region of human PD-1.

    Background

    The programmed cell death 1 protein (PD-1, PDCD1, CD279) is a member of the CD28 family of immunoreceptors that regulate T cell activation and immune responses (1-3). The PD-1 protein contains an extracellular Ig V domain, a transmembrane domain, and a cytoplasmic tail that includes an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). PD-1 is activated by the cell surface ligands PD-L1 and PD-L2 (4). Upon activation, PD-1 ITIM and ITSM phosphorylation leads to the recruitment of the protein tyrosine phosphatases SHP-1 and SHP-2, which suppress TCR signaling (5-7). In addition to activated T cells, PD-1 is expressed in activated B cells and monocytes, although its function in these cell types has not been fully characterized (8). The PD-1 pathway plays an important role in immune tolerance (3); however, research studies show that cancer cells often adopt this pathway to escape immune surveillance (9). Consequently, blockade of PD-1 and its ligands is proving to be a sound strategy for neoplastic intervention (10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.